286 related articles for article (PubMed ID: 17575146)
1. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
Isayeva T; Chanda D; Kallman L; Eltoum IE; Ponnazhagan S
Cancer Res; 2007 Jun; 67(12):5789-97. PubMed ID: 17575146
[TBL] [Abstract][Full Text] [Related]
2. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
3. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiogenesis and tumor progression by hydrodynamic cotransfection of angiostatin K1-3, endostatin, and saxatilin genes.
Kim KS; Kim DS; Chung KH; Park YS
Cancer Gene Ther; 2006 Jun; 13(6):563-71. PubMed ID: 16410825
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.
Zhang X; Xu J; Lawler J; Terwilliger E; Parangi S
Clin Cancer Res; 2007 Jul; 13(13):3968-76. PubMed ID: 17606731
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and prostate cancer: identification of a molecular progression switch.
Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.
Isayeva T; Ren C; Ponnazhagan S
Gene Ther; 2007 Jan; 14(2):138-46. PubMed ID: 16943851
[TBL] [Abstract][Full Text] [Related]
8. Baculovirus vectors for antiangiogenesis-based cancer gene therapy.
Luo WY; Shih YS; Lo WH; Chen HR; Wang SC; Wang CH; Chien CH; Chiang CS; Chuang YJ; Hu YC
Cancer Gene Ther; 2011 Sep; 18(9):637-45. PubMed ID: 21701531
[TBL] [Abstract][Full Text] [Related]
9. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice.
Scappaticci FA; Smith R; Pathak A; Schloss D; Lum B; Cao Y; Johnson F; Engleman EG; Nolan GP
Mol Ther; 2001 Feb; 3(2):186-96. PubMed ID: 11237675
[TBL] [Abstract][Full Text] [Related]
10. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.
Shariat SF; Desai S; Song W; Khan T; Zhao J; Nguyen C; Foster BA; Greenberg N; Spencer DM; Slawin KM
Cancer Res; 2001 Mar; 61(6):2562-71. PubMed ID: 11289132
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.
Mahendra G; Kumar S; Isayeva T; Mahasreshti PJ; Curiel DT; Stockardt CR; Grizzle WE; Alapati V; Singh R; Siegal GP; Meleth S; Ponnazhagan S
Cancer Gene Ther; 2005 Jan; 12(1):26-34. PubMed ID: 15359287
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells.
Indraccolo S; Gola E; Rosato A; Minuzzo S; Habeler W; Tisato V; Roni V; Esposito G; Morini M; Albini A; Noonan DM; Ferrantini M; Amadori A; Chieco-Bianchi L
Gene Ther; 2002 Jul; 9(13):867-78. PubMed ID: 12080381
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene.
Oga M; Takenaga K; Sato Y; Nakajima H; Koshikawa N; Osato K; Sakiyama S
Int J Oncol; 2003 Jul; 23(1):73-9. PubMed ID: 12792778
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
Dzojic H; Loskog A; Tötterman TH; Essand M
Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
[TBL] [Abstract][Full Text] [Related]
19. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
20. Long-term expression of angiostatin suppresses metastatic liver cancer in mice.
Xu R; Sun X; Tse LY; Li H; Chan PC; Xu S; Xiao W; Kung HF; Krissansen GW; Fan ST
Hepatology; 2003 Jun; 37(6):1451-60. PubMed ID: 12774025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
